KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges (2016 - 2021)

Biocryst Pharmaceuticals filings provide 11 years of Amortization of Deferred Charges readings, the most recent being $5.4 million for Q3 2021.

  • On a quarterly basis, Amortization of Deferred Charges rose 1320.47% to $5.4 million in Q3 2021 year-over-year; TTM through Sep 2021 was $15.3 million, a 2016.04% increase, with the full-year FY2023 number at $8.5 million, changed N/A from a year prior.
  • Amortization of Deferred Charges hit $5.4 million in Q3 2021 for Biocryst Pharmaceuticals, up from $3.9 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $5.4 million in Q3 2021 to a low of $209000.0 in Q4 2018.
  • Median Amortization of Deferred Charges over the past 5 years was $255000.0 (2019), compared with a mean of $1.1 million.
  • Biggest five-year swings in Amortization of Deferred Charges: dropped 4.13% in 2018 and later surged 1320.47% in 2021.
  • Biocryst Pharmaceuticals' Amortization of Deferred Charges stood at $218000.0 in 2017, then fell by 4.13% to $209000.0 in 2018, then soared by 63.64% to $342000.0 in 2019, then skyrocketed by 609.94% to $2.4 million in 2020, then soared by 122.9% to $5.4 million in 2021.
  • The last three reported values for Amortization of Deferred Charges were $5.4 million (Q3 2021), $3.9 million (Q2 2021), and $3.5 million (Q1 2021) per Business Quant data.